Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 1/2 2 Phase 1 2 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Lymphoma, Non-Hodgkin 5 Leukemia, Lymphocytic, Chronic, B-Cell 4 Neoplasms 2 Lymphoma, B-Cell, Marginal Zone 2 Arthritis, Rheumatoid 2 Waldenstrom Macroglobulinemia 1 Sjogren's Syndrome 1 Neoplasm, Residual 1 Mediastinal Neoplasms 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Lymphohistiocytosis, Hemophagocytic 1 Lymphatic Diseases 1 Leukemia, B-Cell 1 Leukemia 1 Heart Failure 1 Epstein-Barr Virus Infections 1 Burkitt Lymphoma 1

Interventions

spartalizumab 1 ruxolitinib 1 dolutegravir 1 Rituximab 1 Ritonavir 1 Nucleosides 1 Dexamethasone 1 Darunavir 1 Control Groups 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Epstein-Barr Virus Infections × Rituximab × Clear all

NCT04989491 2024-08-19

REPLY

University Hospital, Strasbourg, France

Phase 4 Recruiting

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡